Maia Pharms Inc patents expiration
1. Bortezomib patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma; Treatment of adult patients with mantle cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
BORTEZOMIB family patents
2. Sincalide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11318100 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(14 years from now) | |
| US11110063 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(14 years from now) | |
Drugs and Companies using SINCALIDE ingredient
Market Authorisation Date: 22 November, 2022
Treatment: Accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract; Stimulat...
Dosage: POWDER;INTRAVENOUS
SINCALIDE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic